Title of scroll burnt to a crisp by Mt Vesuvius 2,000 years ago finally read by AI – & we even know who wrote them
RESEARCHERS have deciphered the title and author of a charred scroll destroyed by the Mount Vesuvius eruption 2,000 years ago.
The tightly bound scroll cannot be opened since its delicate, burnt pages would only fall apart.
6
6
6
Therefore, researchers have used a cutting-edge technique hinging on artificial intelligence (AI) to reveal the lost text.
The scroll was discovered in Herculaneum, an ancient Roman town that was buried under the massive volcanic fallout from Mount Vesuvius.
After 'virtually unwrapping' scroll PHerc. 172, researchers discovered it was titled On Vices by the Greek philosopher Philodemus.
The text offered ancient Romans guidance for cultivating a virtuous life, according to researchers.
Philodemus, who lived between roughly 110 and 30 BCE, was an Epicurean philosopher and poet from Gadara.
The University of Oxford's Bodleian Library holds a number of the scrolls, which have been left untouched for decades.
But recent advancements in technology have allowed the scrolls to be 3D reconstructed with powerful X-ray beams without damaging them.
Once researchers have identified each layer of the scroll, AI is used to detect the ink.
The ink is digitally painted onto the scroll, for researchers to decipher.
As part of an international competition, researchers have found the title and author inside of a sealed scroll for the first time.
The Vesuvius Challenge awards money to all those who can help decipher the charred scrolls housed at the Bodleian Libraries at the University of Oxford.
Researchers behind this latest feat have been awarded the
Vesuvius Challenge First Title Prize, which includes prize money of $60,000.
This was achieved by two parties at roughly the same time - Sean Johnson from the Vesuvius Challenge, and Marcel Roth and Micha Nowak from the University of Würzburg.
The pages of the relic PHerc. 172 were first published in February, the title page had yet to be deciphered.
PHerc.172 is one of roughly 800 scrolls unearthed in the Villa of the Papyri, a luxurious estate believed to have belonged to Lucius Calpurnius Piso Caesoninus, Julius Caesar's father-in-law.
How AI & X-rays are unravelling scroll secrets
AI and X-rays are revolutionising the study of ancient scrolls by enabling researchers to virtually "unroll" and decipher texts that are too fragile to handle physically.
X-rays, particularly advanced methods like X-ray micro-computed tomography (micro-CT), create highly detailed 3D scans of scrolls.
These scans capture the layers of tightly wound or damaged parchment or papyrus without physically unrolling them, preserving their integrity.
X-rays can also detect variations in density caused by metallic or carbon-based inks used in ancient writing.
AI algorithms, particularly those using deep learning, can segment layers of text by identifying and separating individual layers of the scroll from 3D X-ray data, isolating the text for analysis.
They can also recognise text by enhancing faint markings or patterns corresponding to ancient writing, often revealing characters that are invisible to the naked eye.
AI algorithms can reconstruct incomplete sections as well. Machine-learning models can fill in the gaps or predict any missing text.
For scrolls where X-rays detect ink differences, AI can distinguish metallic inks - typically used in later periods of history - from carbon-based inks, enabling a more detailed and context-sensitive interpretation.
Advanced imaging can also track even faint remnants of ink strokes, reconstructing text in incredible detail.
The villa, based in Herculaneum, was thought to house one of the finest libraries of antiquity, including works of Greek philosophy and possibly undiscovered Roman literature.
The first milestone in the Vesuvius Challenge was reached in February 2024, when three students shared a $700,000 prize for reading parts of another scroll.
The success of the competition has attracted tech moguls like Elon Musk, who funded later phases of the competition.
6
6
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
26 minutes ago
- The Sun
Taking common contraceptive pill long-term could increase your risk of life-threatening brain tumour, scientists warn
TAKING a progesterone-only contraceptive pill for more than five years is linked to an increased risk of a life-threatening brain tumour, say scientists. Desogestrel is a synthetic progestogen hormone used in oral contraceptives, specifically the progestogen-only pill (POP) or mini-pill. 1 While it offers several benefits beyond preventing pregnancy, such as regulating the menstrual cycle, reducing heavy or painful periods, new research suggests taking it continuously for more than five years is linked to a small increased risk of developing an intracranial meningioma. An intracranial meningioma is a tumour that develops from the meninges, the layers of tissue that cover the brain and spinal cord. These tumours are typically benign (non- cancerous) and slow-growing. But they can be life-threatening depending on size, location, and growth rate. The tumours are more common in older women, but previous studies lack information on the specific type of progestogen used - and risk has not been measured for continuous, current, and long term use. In the study from France published by The BMJ, researchers set out to assess the real-life risk of the brain tumour and short-term (less than a year) and prolonged (one to seven or more years) use of oral contraceptives containing desogestrel 75µg, levonorgestrel 30µg, or levonorgestrel 50-150 µg combined with oestrogen. Their findings were based on data from the French national health data system (SNDS) for 8,391 women who had undergone surgery for intracranial meningioma in 2020-2023. Each case was matched to 10 control women without meningioma of the same age and area of residence. The results showed a small increased risk associated with use of desogestrel for more than five continuous years. An increased risk wasn't found for shorter durations or when desogestrel had been discontinued for more than one year. Women taking fat jabs need 'effective contraception' - as health chiefs warn of serious harm to unborn babies The risk was greater in women older than 45 and after prolonged use of one of the known high risk progestogens before desogestrel. Although the researchers added the risk disappeared one year after stopping taking the pill. It was estimated that 67,000 women would need to use desogestrel for one woman to need surgery for intracranial meningioma, and 17,000 women if current use was for more than five years. No increased risk was found for levonorgestrel, alone or combined with oestrogen, regardless of duration of use. The researchers suggested desogestrel be discontinued if an intracranial meningioma is identified and patients monitored rather than undergoing immediate surgery. Desogestrel safety Desogestrel, when used as a progestogen-only pill (POP), is generally considered safe and effective, but it has some potential side effects and risks. But it's important to discuss any concerns with a healthcare professional. Highly effective When taken correctly, it's more than 99 per cent effective in preventing pregnancy. No protection against STIs The POP doesn't protect against sexually transmitted infections, so it's essential to use condoms for STI protection. Important to take regularly You need to take it at or around the same time every day, without breaks between packs. Possible side effects Ovarian cysts Some users might develop small, fluid-filled cysts on their ovaries, which are generally not dangerous and often resolve on their own. When to seek medical advice
Daily Mail
26 minutes ago
- Daily Mail
Experts pinpoint exactly how long you need to use a contraceptive pill to increase your risk of a brain tumour
Millions of women taking the mini-pill could be at increased risk of developing a brain tumour, new research suggests. Experts found that women taking the progestogen-only pill—often dubbed 'the mini-pill' continuously for more than five years were more likely to develop a meningioma. Meningiomas accounts for a third of all brain tumours diagnosed in the UK each year. While usually non-cancerous they can still cause problems they grow larger inside the brain. In the new study, French researchers analysed data from over 8,000 women, with an average age of 60, who had surgery for this form of tumour. They found women who did were more likely to have been taking the mini pill—medically called desogestrel for at least five years. However, independent experts have said women on the medication shouldn't panic, as the increased risk is relatively small. Desogestrel, in contrast to the more famous Pill, only contains one sex hormone progestogen. It is primarily taken by women with underlying health conditions that makes taking other contraceptives dangerous, or who suffer adverse side effects when doing so. The NHS says natural family planning can be up to 99 per cent effective when done correctly and around 75 per cent if not used according to instructions. By comparison, the Pill, implant, IUS and IUD are 99 per cent effective with perfect use, while condoms are 98 per cent While the increased risk of a meningioma was observed, the authors—who published their findings in the British Medical Journal —said it was relatively minor. They outlined that only one out of 67,000 women taking desogestrel will develop a meningioma requiring surgery. The scientists also found that there was no increased risk when the mini pill was used for less than five years. They also found that the increased risk disappeared a year after coming off the mini pill. Meningiomas are a tumour of the membrane that surrounds the brain, with more than 90 per cent of these are not cancerous. While not at risk of spreading elsewhere in the body like a cancerous growth they can still cause patients problems. Every year proportion of meningioma patients will need surgery to remove the tumour due to it causing increased internal pressure on the brain. Common symptoms of a meningioma include a persistent headache as well as constant nausea which is often accompanied with drowsiness. Dr Mangesh Thorat, an expert in population health at Queen Mary University of London, who was not involved in the study, said women on the medication shouldn't be alarmed. 'The magnitude of increase in the risk is small, and short-term use is not associated with increased risk and that the excess risk ceases to exist once the use is stopped for more than a year,' he said. He advised women who may be concerned about their risk to contact their GP. 'Talk to your healthcare provider regarding the drug you are using. If it is associated with an increased risk of meningioma, this can be changed to a safer alternative,' he said. Experts say that a limitation of the study is that the researchers only looked at one type of progestogen pill—desogestrel and not other drugs that also include the hormone. Dr Thorat said: 'the study cannot provide information on the formulations not commonly used in France but used in other countries.' He has called on further studies to be undertaken in different countries. Figures currently suggest around 6 per cent of women aged 16 to 49 use the mini pill in the UK—roughly 3.1 million patients. Taken every day, it works by thickening cervical mucus and thinning the womb lining which helps stop sperm reaching an egg and from a fertilised egg attaching itself in the womb. In some cases, the mini pill can also stop ovulation from occurring. It is 99.7 per cent effective with perfect use but if used incorrectly—such as missing a pill or experiencing nausea and diarrhoea while on it—around one in ten women (9 per cent) may get pregnant. Known side effects of the mini pill—proven to be over 99 per cent effective at stopping pregnancy—include nausea, breast tenderness, mood swings and headaches. Others claim they pile on pounds while taking the drug because of increased fluid retention and appetite. However, the NHS says there is no evidence it leads to weight gain. The latest study comes just a month after British scientists found that women with asthma who are taking the mini pill were a third more likely to suffer an attack.
The Independent
4 hours ago
- The Independent
‘Game-changer' new blood test to detect prevalent autoimmune disease without nightmare side effects
People with coeliac disease may soon be able to avoid consuming large quantities of gluten – the substance that triggers their symptoms – to get a diagnosis. New clinical research published in the journal Gastroenterology has shown a 'game-changer' blood test for gluten-specific T cells that can detect coeliac disease – even when no gluten has been consumed. Currently, people with suspected coeliac are required to eat large amounts of gluten for weeks to get an accurate diagnosis. However, researchers said the new blood test could boost rates of diagnosis, identify patients at risk of severe reactions to gluten and detect silent coeliac disease in asymptomatic people. Coeliac disease is an autoimmune condition where the body attacks its own tissues when gluten is eaten, which prevents normal digestion and absorption of food, with the risk of developing serious health complications. It is driven by eating gluten, a protein found in wheat, barley and rye. An estimated 1 in 100 people have it in the UK. However, only 36 per cent with the condition are clinically diagnosed, according to Coeliac UK. Undiagnosed or untreated coeliac disease can result in complications such as osteoporosis, unexplained infertility, neurological dysfunction and, in rare instances, small bowel cancer, Coeliac UK says. Currently, all coeliac testing methods require regular gluten consumption to be effective, the researchers said. Many people are deterred from seeking a definite diagnosis because they do not want to consume gluten and be sick, the Australia-based scientists added. Associate Professor Jason Tye-Din, Head of WEHI's Coeliac Research Laboratory and a gastroenterologist at the Royal Melbourne Hospital, said: 'There are likely millions of people around the world living with undiagnosed coeliac disease simply because the path to diagnosis is difficult, and at times, debilitating.' 'By eliminating the need for a gluten challenge, we're addressing one of the biggest deterrents in current diagnostic practices,' she added. 'This test could be a game-changer, sparing thousands of people the emotional and physical toll of returning to gluten. It's a major step towards faster, safer diagnosis.' The study evaluated the potential of a blood test to measure an immune marker interleukin 2 (IL-2). In 2019, researchers found this immune marker spiked in the bloodstream of people with coeliac disease shortly after they ate gluten. The scientists used blood samples from 181 volunteers, including 75 people with treated coeliac disease, 13 with active, untreated coeliac disease, 32 people with non-coeliac gluten sensitivity and 61 healthy people. Participant blood samples were then mixed with gluten in a test tube for a day to see if the IL-2 signal appeared. The team was 'thrilled' to find the test could detect the condition with up to 90 per cent sensitivity and 97 per cent specificity – even in patients following a strict gluten-free diet, PhD researcher Olivia Moscatelli, who was diagnosed with coeliac disease at 18, said. The IL-2 signal only increased in the volunteers with coeliac disease, showing the immune response to gluten can be detected in a tube, without the need to consume gluten, researchers said. Ms Moscatelli said the test also performed exceptionally well in people with coeliac disease who had other autoimmune conditions, such as type 1 diabetes or Hashimoto's thyroiditis. The Walter and Eliza Hall Institute team are now collaborating with Novoviah Pharmaceuticals to confirm the test's accuracy across diverse populations and find real-world data.
